CTLA-4 exists as membrane (mCTLA-4) and soluble (sCTLA-4) forms. Immunological roles of sCTLA-4 are scarcely known. With mice deficient in either sCTLA-4 or mCTLA-4, Osaki et al. show that sCTLA-4, which is predominantly produced by Treg cells, suppresses type 1 immunity while allowing type 2 immunity in chronic inflammation.
Tag: Cancer Immunotherapy
Correction: Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancersLeveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer
SITC strategic vision: prevention, premalignant immunity, host and environmental factors
Cancer immunotherapy has improved the survival of a subset of patients by harnessing the power of the immune system to find and destroy malignant cells. The immune system also protects the host by destroying developing premalignant and malignant tumors. Advancing our knowledge of premalignant immunity and immune changes seen in lesions that develop into invasive… Continue reading SITC strategic vision: prevention, premalignant immunity, host and environmental factors
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Introduction Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors, but they also commonly cause immune-related adverse events (irAEs). The predictive features of clinically severe irAEs leading to cessation of ICIs have yet to be established. Given the similarities between irAEs and autoimmune diseases, we sought to investigate… Continue reading Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Background B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell immunotherapy has shown promising results in the treatment of relapsed or refractory multiple myeloma (R/RMM). This study presents the updated long-term outcomes from our center. Methods Between July 30, 2018, and September 27, 2023, 141 patients with R/RMM who received BCMA CAR-T therapy were enrolled.… Continue reading Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment
Background Increasing numbers of patients diagnosed with advanced cancer survive long-term after treatment with immune checkpoint inhibitors (ICIs). To design adequate interventions for these survivors, knowledge regarding quality of life (QOL) and its association with long-term and late effects of ICI treatment is required. Therefore, this study aimed to evaluate QOL, neurocognitive function, psychological issues,… Continue reading Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment
[ASAP] Design, Synthesis, Evaluation, and SAR of 5-Phenylisoindoline Derivatives, a Potent Class of Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction
Personalized Vaccines and Beyond: Confronting the Complex Biology of Kidney Cancer
Breakthroughs in kidney cancer research, including new insights into the tumor-immune microenvironment and the identification of metabolic vulnerabilities, are reshaping the future of treatment, creating opportunities for therapies tailored specifically to individual patients. These cutting-edge developments in personalized vaccines targeting tumor-specific mutations, novel cell therapies, and biomarkers that can predict treatment responses, could help to… Continue reading Personalized Vaccines and Beyond: Confronting the Complex Biology of Kidney Cancer
Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial
Background Irreversible electroporation (IRE) and stereotactic ablative body radiotherapy (SABR) are cytoreductive therapies for locally advanced pancreatic cancer (LAPC). Both may signify immunogenic cell death. We aimed to compare systemic immune responses between the treatments. Methods As part of the randomized phase II CROSSFIRE trial (NCT02791503), comparing the oncological efficacy of IRE to SABR in… Continue reading Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial